Hepatocellular carcinoma treatment: a comparative review of emerging growth factor receptor antagonists
Sign Up to like & getrecommendations! Published in 2017 at "Expert Opinion on Emerging Drugs"
DOI: 10.1080/14728214.2017.1330886
Abstract: ABSTRACT Introduction: Hepatocellular carcinoma (HCC) is a leading cause of death worldwide. Over the last decade, sorafenib has been the only available therapeutic option for advanced HCC, although regorafenib recently showed a survival benefit compared… read more here.
Keywords: hepatocellular carcinoma; comparative review; carcinoma; treatment comparative ... See more keywords